A Phase 1 interventional study of APX001 with Standard of Care anti-fungal agent in Acute Myeloid Leukemia, sponsored by Basilea Pharmaceutica. Completed at 3 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-17.
Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 282 studies in Leukemia, Myeloid, Acute with a site in Germany — 32 open to participants now, 55 under way, 18 of them phase 3. Leukemia, Myeloid, Acute · Germany.
Among the 282 studies in Leukemia, Myeloid, Acute with a site in Germany, this one is the 229th largest by enrollment of the 262 interventional ones that give a count, is one of 20 that started in 2017, is one of 46 in phase 1, and was the 191st registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →32 of the 282 studies in Leukemia, Myeloid, Acute with a site in Germany are open now. Recruiting first, the newest first:
University of Freiburg · Sites in Germany
Ages 18+
Stichting Hemato-Oncologie voor Volwassenen Nederland · Sites in Germany, United States, Australia and 10 more countries
Ages 18+
University Hospital Tuebingen · Sites in Germany
Ages 18–75 · Healthy volunteers
Technische Universität Dresden · Sites in Germany
Ages 18+
AstraZeneca · Sites in Germany, United States, Australia and 6 more countries
Ages 16+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
282 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 95 · Phase 2 128 · Phase 3 88 · Phase 4 5
First in 1993; this study’s year is marked. 20 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 127 across the 262 interventional studies, 135 across the 18 observational. Of the 204 that completed or were terminated, 76 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
148 of 282 have an industry lead sponsor. The 10 most frequent:
Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.
Basilea Pharmaceutica has 2 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
15 of the studies in Leukemia, Myeloid, Acute with a site in Germany that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT03839771Phase 3Stichting Hemato-Oncologie voor Volwassenen NederlandA Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy | 2027-04-17 |
| NCT05429632Phase 3Priothera SASMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | 2027-05 |
| NCT03897127Phase 3University of UlmStudy of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics | 2027-06 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 282 studies in Leukemia, Myeloid, Acute with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open-label, multi-center, Phase Ib study to determine the safety and pharmacokinetics of intravenous and oral APX001 in patients undergoing chemotherapy for Acute Myeloid Leukemia with neutropenia.
A total of 20 patients will be enrolled in this study. 10 patients in Cohort I, intravenous drug dosing and 10 patients will be enrolled in Cohort II, oral drug dosing.
All patients will receive chemotherapy for their AML according to local clinical standard of care as well as antifungal prophylaxis.
APX001 will be administered for 14 consecutive days, beginning on Study Day 3 after onset of chemotherapy
Key Inclusion Criteria:
Key Exclusion Criteria:
Drug: APX001 with Standard of Care anti-fungal agent
safety assessment
Number of patients with treatment-related adverse events as assessed and reported by CTCAE v4.0
Time frame: One to forty-four days
Area under the plasma concentration versus time curve (AUC)
Time frame: One to forty-four days
Peak Plasma Concentration (Cmax)
Time frame: One to forty-four days
Ran from Nov 2017 to primary completion in Oct 2018, 10 months.
Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 10 months is below that.
Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.